Figure 2. Competing risk analysis for the development of cardiovascular adverse events in women with breast cancer who were treated with CDK4/6 inhibitors vs those treated with anthracyclines.*.

A, Any CVAE; B, hypertension; C, cardiomyopathy/heart failure; D, atrial fibrillation/flutter. *Covariates in the adjusted analysis included age, race and ethnicity, obesity, diabetes, preexisting hypertension, and hyperlipidemia. AFib/Aflutter indicates atrial fibrillation/atrial flutter; CDK, cyclin‐dependent kinase; CVAE, cardiovascular adverse event; and HR, hazard ratio.